

How can patients and providers best contribute to the HTA process

Sime Warren, National Health Care Institute of the Netherlands, Diemen, the Netherlands
Anna Nachtnebel, Ludwig Boltzmann Institute for HTA, Vienna, Austria
WP5 - Applying the HTA Core Model for Rapid Assessment for national adaptation and reporting

Third WP2 Face to Face Training Course for EUnetHTA stakeholders, Brussels, 23rd of April 2015

Stakeholder involvement Strand A and Strand B

Stakeholder Involvement Strand A


Close collaboration with the participating manufacturer



Update of the HTA Core Model application for REAs → Stakeholder and public consultation

Feedback session with manufacturer about the draft submission template (WP7)

Stakeholder Involvement Strand B



Abbreviations: SAG – Stakeholder Advisory Group. SF - Stakeholder Forum. REA – Relative Effectiveness Assessment

Stakeholder involvement - Scoping Phase

Compilation of final project plan

- ❖ **Stakeholder Advisory Group & Stakeholder Forum:** informed about upcoming public consultation of project plan, inquiry to suggest external medical experts, patients representatives, identification of manufacturers
- ❖ **Manufacturer(s):** informed about upcoming public consultation of project plan, to submit evidence/information on reimbursement status, submission file, scoping meeting(?)
- ❖ **Patients:** scoping - selection of relevant outcomes, comparators, draft project plan
- ❖ **Medical experts:** scoping - selection of relevant outcomes, comparators, draft project plan
- ❖ **Public:** draft project plan



Stakeholder involvement - Assessment Phase

Production of final assessment

Manufacturer(s), patients, medical experts: opportunity to comment on second draft of assessment, comments & answers publicly available

Further involvement

Update of HTA Core Model for Rapid REA

Plenary session Strand A and Strand B

1. Where do you think stakeholder involvement is most relevant?



2. Could you think of other ways of stakeholder involvement?

Thank you!

This presentation arises from the EUnetHTA Joint Action 2 which has received funding from the European Union, in the framework of the Health Programme

